ID
45987
Description
Principal Investigator: Paul K. Paik, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Squamous Cell Carcinoma,Nonsmall Cell Lung Cancer https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000907 Putative oncogenic pathways in squamous cell lung cancer have been recently characterized, although their biologic repercussions in patients is largely unknown. This study sought to discover potential clinical manifestations of major pathways in squamous cell lung cancer, particularly the PI3K pathway. Two key findings emerged: patients with stage IV squamous cell lung cancer whose tumors harbored upstream PI3K aberrations had significantly worse survival and a higher burden of metastatic disease. In addition, brain metastases were significantly more common in these patients than in others. Paired lung primary/brain metastasis genotyping, including RNA sequencing and whole exome sequencing, uncovered a high degree of genetic heterogeneity between lung/brain pairs, and identified potential regulators of the metastatic process to brain.
Link
Keywords
Versions (1)
- 06/04/2024 06/04/2024 - Madita Rudolph
Copyright Holder
Paul K. Paik, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Uploaded on
6 avril 2024
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000907 Brain Metastases in Squamous Cell Lung Cancers
This subject phenotype table contains subject ID, race, age, sex, smoking status, and pack years of participant.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status for lung cancer.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject ID, race, age, sex, smoking status, and pack years of participant.
- This sample attributes table contains sample ID, body site where sample was collected, analyte type, tumor status, histological type, sample type (primary tumor, metastasis or transformed cell line), primary tumor location, tumor stage, tumor grade, tumor treatment, and names of the center which conducted genotyping and sequencing.
Similar models
This subject phenotype table contains subject ID, race, age, sex, smoking status, and pack years of participant.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status for lung cancer.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject ID, race, age, sex, smoking status, and pack years of participant.
- This sample attributes table contains sample ID, body site where sample was collected, analyte type, tumor status, histological type, sample type (primary tumor, metastasis or transformed cell line), primary tumor location, tumor stage, tumor grade, tumor treatment, and names of the center which conducted genotyping and sequencing.
C2348585 (UMLS CUI [1,2])
No comments